Purpose: The findings of EGFR mutations and the development of targeted therapies have significantly improved the overall survival of lung cancer patients. Still, the prognosis remains poor, so we need to know more about the genetic alterations in lung cancer. MicroRNAs are dysregulated in lung cancer, and microRNAs can regulate EGFR. So it is very important to predict the candidate microRNAs that target mutated EGFR and to investigate the role of these candidate microRNAs in lung cancer.
Introduction
Lung cancer, one of the most common malignant tumor 1 , led to the most cancer death in the world. The prevalence and mortality of the lung cancer is still rising. In all new diagnosed lung cancer, non-small cell lung cancer (NSCLC) accounts for approximately 85%, which varies both in molecular and clinical presentation. Despite years of research, the 5-year survival is only about 18%. 2 The discovery of key driver mutations has led to a more personalized approach in the treatment of advanced lung cancer. The activating mutations of EGFR implicate sensitivity to EGFR tyrosine kinase inhibitors. EGFR exon 19 deletion and L858R substitution in exon 21 have been extensively proved to be the sensitive mutations. However, the efficacy of EGFR-TKIs varies among different sensitive EGFR mutations. Several studies have reported that the advanced NSCLC patients with EGFR exon 19 deletion had a longer overall survival (OS) and/or progression-free survival (PFS) with the treatment of gefitinib or erlotinib compared with those with the L858R mutation. [3] [4] [5] [6] MicroRNAs are evolutionarily conserved, endogenous small non-coding RNAs with 18-25 nucleotides that have important functions in diverse biological processes, such as cell proliferation, differentiation, and apoptosis. [7] [8] [9] Furthermore, microRNAs play an essential role in behaving either as oncogenes or tumor suppressor genes 10 .
Increasing evidence indicates that dysregulation of specific microRNAs contributes to the development and progression of cancer, including lung cancer. [11] [12] [13] Moreover, microRNAs can regulate EGFR. 14 So it is important to make it clear that the candidate microRNAs regulating EGFR exon 19 deletion because it might spark the design of novel therapeutics to combat the resistance to EGFR-TKIs or develop new targeted therapy.
In this study, we conducted an explorative microRNAs expression study in two groups of lung adenocarcinoma cell lines, including EGFR exon 19 deletion group (H1650 and PC-9 ) and EGFR wild-type group (A549 and H1299), using microRNA microarrays. Our main focus was the different microRNAs in the two groups. The selected microRNAs were confirmed using qRT-PCR in the cell lines and then we measured 3 microRNAs expressed differently in cell lines in the serum of 14 non-smoking female lung adenocarcinoma patients with wt EGFR and 13 patients with EGFR 19 del. Accordingly we discussed the association of microRNAs with EGFR exon 19 deletion.
Material and Methods

Cell lines and cell culture
Human adenocarcinoma cell lines PC-9 and H1650 (harboring EGFR exon 19 deletion) and A549 and H1299 (harboring wild-type EGFR) were provided by Cancer Institute of Tongji University Medical School, China. All these cells were cultured at 37°C with 5% CO 2 in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 100 U/ml penicillin and 100 mg/ml streptomycin.
Patient enrollment and serum samples
All patients in the study were recruited form Shanghai Pulmonary Hospital, Tongji University Medical School, between January 2012 and June 2014. The patients were newly diagnosed and histologically confirmed primary lung adenocarcinoma. Patients with the previous history of cancer , radiotherapy or chemotherapy were excluded.
The study was approved by an ethical review committee at Tongji University Institutional Care and Use Committee. All blood serum samples were collected and put into a liquid nitrogen tank for long-term storage until microRNAs extraction.
Total RNA isolation
Total RNA was extracted from cells using TRIZOL Reagent (Invitrogen, USA). The RNA concentration and purity were accessed by OD260/OD280 (≥1.6) and OD260/OD230 (≥1.0), and the RNA yield and quality were checked (RIN≥5.0) using Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).
Human microRNAs OneArray®
Human microRNA OneArray® v3 (Phalanx Biotech Group, Taiwan) contains triplicated 1,711 unique microRNA probes from Human (miRBase Release v17), each printed in technical triplicate, and 189 experimental control probes.
Microarray analysis
Small RNA was pre-enriched by Nanoseplook (Pall Corporation, USA) from 2.5 μ g total RNA samples and labeled with microRNAs ULSTM Labeling Kit (Kreatech Diagnostics, The Netherlands). Labeled targets were hybridized to the Human microRNA OneArray® v3 with OneArray® Hybridization System. After 16 hours hybridization at 37 , non-specific binding targets were washed away by three different washing steps (Wash 37 5 mins； Wash 37 , 5 mins 25 5 mins; Wash III rinse 20 times), and the slides were dried by centrifugation and scanned by an Axon 4000B scanner (Molecular Devices, Sunnyvale, CA, USA). Normalized spot intensities were transformed to gene expression log2 ratios between the mutation and wild-type group. The spots with log2 ratio ≥ 1 or log2 ratio ≤ -1 and P-value < 0.05 were tested for further analysis.
Validation by qRT-PCR
Quantitative real time-PCR (qRT-PCR) was carried out on the 7900HT thermocycler (Applied Biosystems, Foster City, CA). U6 was used for internal controls. The data were managed using the Applied Biosystems software RQ. Relative expression was calculated using the comparative Ct method and obtaining the fold-change value (2 -ΔΔCt ). Data analyses were performed via GraphPad Prism v6.00. μ L water. The droplets generated from each sample were transferred to a 96-well PCR plate (Eppendorf, Germany). PCR amplification was carried on a T100 thermal cycler (QuantStudio™ 3D Digital PCR System) at 96℃for 10 min, followed by 39 cycles 60℃ for 2 min, then 98℃ for 0.5 min. For Final extension， followed by 60℃ for 2 min, Last，Storage is at 10℃ for 100min. 15 
EGFR mutation analyses
Results
Microarrays analysis of cell lines with EGFR exon 19 deletion compared with wild-type
To identify microRNAs that were differentially expressed between cell lines with EGFR exon 19 deletion and the wild-type adenocarcinoma cell lines, the expression profiles of microRNAs (1,711 microRNAs) were assessed using microRNA microarrays. For clustering analysis, 260 genes was selected to identify differentially 
Validation of the microarrays results using quantitative reverse transcriptase polymerase chain reaction (qRT-PCR)
The eleven microRNAs, differentially expressed in the two cell groups in microarray analyses, were validated by qRT-PCR. As a result, six microRNAs were identified and differentially expressed between the two cell groups (see Table 2 ). Hsa-miR-141-3p, hsa-miR-200c-3p, hsa-miR-203, hsa-miR-3182, and hsa-miR-934 were up-regulated, while hsa-miR-3196 was down-regulated ( Figure 2 ).
Pathway analysis
Using the microRNA target filter in TargetScan Release 6.2, we searched for genes involved in the signaling pathways that are experimentally observed or highly predicted to be regulated by the selected microRNAs. The six microRNAs that were differentially expressed between EGFR exon 19 deletion and EGFR wild-type cell lines were associated with 3181 mRNA targets. Two microRNAs (hsa-miR-200c-3p, hsa-miR-203) were experimentally confirmed to target EGFR, and be associated with EGFR-TKI resistance. [16] [17] 
Circulating microRNAs in relation to EGFR exon 19 deletion
This study was conducted on 27 participants stratified into EGFR exon 19 deletion group and wild-type group. Selected candidates were non-smoking lung adenocarcinoma patients. It is well known that the sensitivity of qPCR for the detection of the low copy genes is not so high, as it only can resolve ∼ 1.5-fold changes of nucleic acids. 18 Given that a portion of the cancer-related microRNAs is derived from primary tumor and could be 'diluted' in the normal microRNAs, [19] [20] [21] the microRNAs presenting at low levels in serum could be undetectable by qPCR.
Droplet digital PCR is a direct method for quantitatively detecting nucleic acids. 22, 23 It depends on limit ptoportition of the PCR volume, in which a positive microreactions indicates the presence of a single molecule in a given reaction. The number of positive reactions, together with Poisson's distribution, can be used to calculate the original target concentration in a straight and high-confidence measurement method. 24 In our study, digital PCR was used to detect three circulating microRNAs (hsa-miR-200c-3p, hsa-miR-203, hsa-miR-3196) of 27 patients, 13 patients with EGFR exon 19 deletion and 14 wild-type EGFR. In the results, we found that hsa-miR-3196 was down-regulated in the group of EGFR exon 19 deletion compared with wild-type, which was consistent with our results of cell study (Figure 3 ).
Discussion
In the present work，we found eleven microRNAs differentially expressed between and tumor growth in vivo. 29, 30 In line with our results, miR-203 overexpression resulted in increased sensitivity to gefitinib-induced apoptosis in nude mice after two weeks of treatment. 31 The function of hsa-miR-934 is unknown, but it is located in intron 4 of the vestigial-like 1 (VGLL1) gene. The miR-934 was the most strongly up-regulated microRNA in triple-negative IDCs (61.5-fold increase with respect to ER+ breast carcinomas). 32 Though studies of hsa-miR-3196 are rare, it was found that miR-3196 was down-regulated in basal cell carcinoma compared with nonlesional skin, 33 and was also down-regulated in PTC patients with non-(131) I-avid lung metastases versus (131)I-avid lung metastases. 34 Regarding hsa-miR-3182, there is still no published study.
A large number of microRNAs have been found to be stably expressed in human serum and plasma 35, 36 . Circulating microRNAs or their expression profiles have been proposed to be useful biomarkers of the diagnosis and prognosis of cancer.
Overexpressed serum miR-21 was associated with the poor survival, lymph node metastasis and advanced stage of NSCLC. 37 As previously stated, very little is known about miR-3196, but the data from the next deletion compared with wild-type. 
